Literature DB >> 11233666

Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families.

S Vermeire1, M Peeters, R Vlietinck, S Joossens, E Den Hond, V Bulteel, X Bossuyt, B Geypens, P Rutgeerts.   

Abstract

BACKGROUND: Serologic markers anti-Saccharomyces cerevisiae antibodies (ASCA) and antineutrophil cytoplasmic antibodies with perinuclear staining (pANCA) have been proposed to study the immunopathogenesis of IBD. Their measurement may allow better phenotyping of the disease and the detection of subclinical disease. AIMS: To test the hypothesis that serological markers identify an immunologic trait related to disease susceptibility. We also wanted to test the hypothesis that ASCA is a marker related to abnormal tissue permeation by common antigens.
METHODS: We studied the prevalence of pANCA and ASCA in a large cohort of sporadic and familial inflammatory bowel diseases and their unaffected relatives and spouses. Kinetics of ASCA was studied and the relationship between ASCA and 51Cr-EDTA intestinal permeation was investigated.
RESULTS: ASCA was associated with sporadic Crohn's disease (CD) (63%), with Crohn's patients belonging to pure CD families (62%) and also with their unaffected family members (21%). pANCA was associated with UC (58%). The prevalence of ASCA in CD patients belonging to mixed families was strikingly low (33%). ASCA was a stable marker throughout the disease and was not related to an increased small intestinal permeability.
CONCLUSION: ASCA is strongly associated with familial CD in Belgium, and 21% of healthy family members also display the marker. The association is much weaker in patients belonging to mixed families. ASCA is a stable marker and is not a secondary phenomenon due to increased intestinal permeability.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11233666     DOI: 10.1097/00054725-200102000-00002

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  48 in total

Review 1.  Diagnostic methodologies: serology, endoscopy, and radiology.

Authors:  T Dassopoulos
Journal:  Curr Gastroenterol Rep       Date:  2001-12

2.  Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn's disease: a meta-analysis.

Authors:  Zhaoxia Zhang; Chen Li; Xinmei Zhao; Chaolan Lv; Qiong He; Shan Lei; Yandong Guo; Fachao Zhi
Journal:  Dig Dis Sci       Date:  2012-06-06       Impact factor: 3.199

3.  Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy.

Authors:  I E A Hoffman; P Demetter; M Peeters; M De Vos; H Mielants; E M Veys; F De Keyser
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

Review 4.  Host-microbiome interaction in Crohn's disease: A familiar or familial issue?

Authors:  Andrea Michielan; Renata D'Incà
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

5.  Pattern recognition receptor and autophagy gene variants are associated with development of antimicrobial antibodies in Crohn's disease.

Authors:  Travis B Murdoch; Wei Xu; Joanne M Stempak; Carol Landers; Stephan R Targan; Jerome I Rotter; Mark S Silverberg
Journal:  Inflamm Bowel Dis       Date:  2012-01-24       Impact factor: 5.325

Review 6.  Relevance of serologic studies in inflammatory bowel disease.

Authors:  Gwenola Vernier; Boualem Sendid; Daniel Poulain; Jean-Frédéric Colombel
Journal:  Curr Gastroenterol Rep       Date:  2004-12

7.  Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease.

Authors:  J Halfvarson; A Standaert-Vitse; G Järnerot; B Sendid; T Jouault; L Bodin; A Duhamel; J F Colombel; C Tysk; D Poulain
Journal:  Gut       Date:  2005-04-29       Impact factor: 23.059

8.  CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients.

Authors:  B Vander Cruyssen; H Peeters; I E A Hoffman; D Laukens; P Coucke; D Marichal; C Cuvelier; E Remaut; E M Veys; H Mielants; M De Vos; F De Keyser
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

9.  Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease.

Authors:  E Israeli; I Grotto; B Gilburd; R D Balicer; E Goldin; A Wiik; Y Shoenfeld
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

10.  ASCA: genetic marker, predictor of disease, or marker of a response to an environmental antigen?

Authors:  F Seibold
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.